BioMarin to Buy Amicus in $4.8 Billion Bet on Rare Diseases

BioMarin Pharmaceutical Inc. agreed to buy Amicus Therapeutics Inc. for about $4.8 billion, helping the biotech company expand its portfolio of treatments for rare diseases.

Amicus shareholders will receive $14.50 a share in cash, a 33% premium to the last closing price. The deal is expected to close in the second quarter of 2026 subject to shareholder and regulatory approval, the companies said in a statement Friday.